Follicular lymphoma is a lymphoproliferative disorder that is characterized by indolent development with a relative long survival. Patients with advanced diseases and clinical events should; however, receive immediate treatment. Targeted therapy plays an important role in the treatment of follicular lymphoma. Rituximab is an anti-CD20 monoclonal antibody. When used in monotherapy or in combination with chemotherapy as an induction therapy or when given as a maintenance therapy, rituximab has resulted in not only high remission rate but also improved survival. This article reviewed the characteristics of follicular lymphoma. We also discussed current researches on the use of rituximab and the potential clinical applications of this monoclonal antibody for the management of follicular lymphoma.